Neuroscience focus of AstraZeneca, Vanderbilt deal
Vanderbilt University has joined forces with AstraZeneca PLC in a research deal to identify potential treatments for psychosis and other psychiatric symptoms associated with diseases such as Alzheimer’s and schizophrenia
Dr. Mike Poole, vice president of the AstraZenecaNeuroscience Innovative Medicines Unit, said the combination of "AstraZeneca'sdeep experience in drug development and translational science with VCNDD'sexpertise in drug discovery is an important step toward bringing new medicinesforward for people who are suffering from neurodegenerative diseases."